Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 9, 2025 (2 years ago)

Wegovy (semaglutide)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14.

Affected NDC 0169-4524-14

Compare with the code on your package — it is the most precise check available.

Drug: Semaglutide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Wegovy
semaglutide
NDC 00169-4524
2.4 mg/.75mL Injection, Solution
Subcutaneous
Novo Nordisk Pharmaceutical Industries, LP Rx
Recalling firm
Cardinal Health Inc.
NDC code
0169-4524-14
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0393-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Semaglutide recalls

See all
Class II · Moderate risk

SEMAGLUTIDE 20mg

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Ongoing Particulate / foreign matter Apollo Care, LLC NDC 71170-724-04 D-0757-2026
Class II · Moderate risk

SEMAGLUTIDE 10mg

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Ongoing Particulate / foreign matter Apollo Care, LLC NDC 71170-722-02 D-0756-2026
Class II · Moderate risk

SEMAGLUTIDE 7.5mg

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Ongoing Particulate / foreign matter Apollo Care, LLC NDC 71170-721-01 D-0755-2026
Class II · Moderate risk

SEMAGLUTIDE 5mg

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Ongoing Particulate / foreign matter Apollo Care, LLC NDC 71170-712-03 D-0754-2026
Class II · Moderate risk

SEMAGLUTIDE 2.5mg

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Ongoing Particulate / foreign matter Apollo Care, LLC NDC 71170-711-02 D-0753-2026

Other recalls by Cardinal Health Inc.

All 2025 recalls
Class II · Moderate risk

Enoxaparin Sodium Injection

Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL

Ongoing Labeling / mix-up Cardinal Health Inc. NDC 55154-3543-5 D-0597-2025
Class II · Moderate risk

Recombinate

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. D-0573-2025
Class II · Moderate risk

Xolair (omalizumab injection)

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Ongoing Temperature excursion Cardinal Health Inc. NDC 50242-214-55 D-0572-2025